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Abstract
Modafinil is a central nervous system stimulant used to promote wakefulness, and it is being
evaluated clinically as an agonist-based medication to treat stimulant abuse. This is the first report
of the effects of modafinil on the abuse-related effects of cocaine in nonhuman primates. Three
studies were conducted to examine the behavioral effects of modafinil. In the first study, the
discriminative stimulus effects of modafinil were evaluated in monkeys trained to discriminate
either low (0.18 mg/kg, IM) or high (0.4 mg/kg, IM) doses of cocaine from saline. Modafinil dose-
dependently substituted for cocaine in 6/7 monkeys. In the second study, the effects of chronically
administered modafinil (32-56 mg/kg/day, IV) on food- and cocaine-maintained operant
responding were examined. Modafinil was administered 3 times/hr for 23 hr/day to ensure stable
drug levels. Chronic treatment with 32 mg/kg/day modafinil selectively reduced responding
maintained by intermediate (0.003 mg/kg/inj) and peak (0.01 mg/kg/inj) reinforcing doses of
cocaine, but responding maintained by higher doses of cocaine was unaffected. Food-maintained
behavior did not change during chronic treatment with modafinil. In a third study, after extinction
of cocaine self-administration, modafinil (32 and 56 mg/kg/day, IV) significantly increased saline
self-administration on the first day of treatment. These findings indicate that modafinil shares
discriminative stimulus effects with cocaine and selectively reduces responding maintained by
reinforcing doses of cocaine. These data are generally consistent with clinical findings and provide
new evidence that these preclinical models may be useful for predicting the effectiveness of novel
medications for drug abuse treatment.
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INTRODUCTION
Modafinil is an FDA approved stimulant medication used to treat sleep-wakefulness
disorders (Keating & Raffin, 2005; Schwartz, 2009). Modafinil affects several
neurotransmitter systems, but its primary mechanism of action remains elusive. Recent
evidence suggests that modafinil binds with weak affinity to the dopamine transporter
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(DAT) and inhibits dopamine uptake, thereby increasing extracellular dopamine at clinically
relevant doses (Madras et al., 2006; Mignot, Nishino, Guilleminault, & Dement, 1994;
Zolkowska et al., 2009). A recent PET imaging study in humans supports these preclinical
findings (Volkow et al., 2009).
Despite its ability to increase extracellular dopamine levels, modafinil's abuse liability
appears relatively low (Jasinski, 2000; Jasinski & Kovacevic-Ristanovic, 2000; Myrick,
Malcolm, Taylor, & LaRowe, 2004). Modafinil produces some stimulant-like positive
subjective effects (Jasinski, 2000; Makris, Rush, Frederich, Taylor, & Kelly, 2007; Rush,
Kelly, Hays, Baker, & Wooten, 2002; Vansickel, Fillmorex, Hays, & Rush, 2008) and
cocaine-like discriminative stimulus effects in some human subjects (Rush, Kelly, Hays,
Baker et al., 2002). However, modafinil's effects were weak in comparison to cocaine and
amphetamine. Studies of the positive reinforcing effects of clinically relevant doses of
modafinil (200-400 mg) have been inconsistent. One recent clinical laboratory study found
that modafinil (200-600 mg) was not self-administered by cocaine-experienced individuals
(Vosburg, Hart, Haney, Rubin, & Foltin, 2010) but another study reported that modafinil
(200-400 mg) produced reinforcing effects under certain experimental conditions (Stoops,
Lile, Fillmore, Glaser, & Rush, 2005).
In preclinical models, modafinil partially substituted for the discriminative stimulus effects
of cocaine in rats (Dopheide, Morgan, Rodvelt, Schachtman, & Miller, 2007; Gold &
Balster, 1996), but data describing modafinil's reinforcing effects are inconsistent. In rats,
doses as high as 1.7 mg/kg/inj modafinil failed to maintain self-administration (Deroche-
Gamonet et al., 2002), whereas modafinil (0.03 to 0.32 mg/kg/inj) maintained responding at
levels comparable to cocaine in rhesus monkeys (Gold & Balster, 1996). However, the
cumulative doses of modafinil that were reinforcing were 3-6-fold greater than doses used
clinically (Gold & Balster, 1996). These findings indicated that doses of modafinil outside
the clinically relevant dose range are necessary to achieve reinforcing effects.
Modafinil's relatively low abuse liability and weak psychomotor stimulant effects suggest
that it may be useful as an agonist-based medication for treating stimulant-dependence
disorders (Haney & Spealman, 2008; Herin, Rush, & Grabowski, 2010; Martinez-Raga,
Knecht, & Cepeda, 2008; Preti, 2007; Vocci & Elkashef, 2005). Agonist-based
pharmacotherapies have proven useful in treating opioid and nicotine dependence and are
being evaluated for treatment of stimulant abuse (Grabowski, Shearer, Merrill, & Negus,
2004; Herin et al., 2010). For example, putative medications such as amphetamine are
effective in reducing cocaine abuse (Grabowski et al., 2001; Shearer, Wodak, van Beek,
Mattick, & Lewis, 2003). Several clinical studies have reported that modafinil attenuated
some abuse-related effects of cocaine. In clinical laboratory studies, modafinil reduced the
positive subjective effects of cocaine (Dackis et al., 2003; Hart, Haney, Vosburg, Rubin, &
Foltin, 2008; Malcolm et al., 2006), and the reinforcing effects of smoked cocaine (Hart et
al., 2008). In outpatient studies, modafinil reduced cocaine use in subjects who also received
cognitive behavioral therapy (Dackis, Kampman, Lynch, Pettinati, & O'Brien, 2005). Most
recently, a multi-center, double-blind, placebo-controlled 12-week clinical trial of modafinil
was conducted in 125 cocaine-dependent subjects (Anderson et al., 2009). The major finding
was that modafinil decreased craving and cocaine use, but only in subjects without co-
morbid alcohol dependence (Anderson et al., 2009). Several clinical studies have examined
modafinil as a treatment for methamphetamine dependence, but the findings were less
encouraging (De La Garza, Zorick, London, & Newton, 2009; Heinzerling et al., 2010;
McElhiney, Rabkin, Rabkin, & Nunes, 2009; McGaugh et al., 2009).
This is the first evaluation of the effects of chronic modafinil treatment of cocaine
administration by cocaine-experienced non-human primates. To date, only one preclinical
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study has examined the ability of modafinil to modulate the abuse-related effects of cocaine
(Deroche-Gamonet et al., 2002). Acute administration of modafinil (32, 64 or 128 mg/kg,
IP) failed to alter cocaine self-administration during repeated administration in rats
(Deroche-Gamonet et al., 2002). The purpose of the present study was to evaluate the effects
of chronic modafinil treatment on cocaine self-administration in rhesus monkeys and to
characterize the stimulus effects of modafinil in both cocaine discrimination and cocaine
reinstatement paradigms. Modafinil produced cocaine-like discriminative stimulus effects,
and chronic treatment with 32 mg/kg/day modafinil selectively reduced responding
maintained by some reinforcing doses of cocaine without altering food-maintained
responding. In addition, after extinction of cocaine self-administration, modafinil
administration reinstated saline responding. These findings are consistent with results from
most clinical laboratory and outpatient trials described earlier. The concordance between
clinical and preclinical evaluations of modafinil provide further support for the validity of
these preclinical behavioral models (Mello, 2005). These data also encourage the further




Three experiments were conducted in eleven adult rhesus monkeys (Macaca mulatta) that
weighed 6 to 9 kg. The effects of acute modafinil administration on cocaine discrimination
were studied in seven monkeys (four males and three females). Four other male monkeys
were used to examine the effects of chronic modafinil administration on food and cocaine
self-administration and reinstatement. These monkeys had self-administered cocaine under
the same experimental conditions for over 30 months. Chow (Purina Jumbo Monkey Chow
#503), fresh fruit daily and vitamins were given to maintain 95% free feeding weights.
Water was freely available at all times. Animal maintenance and research were conducted in
accordance with the guidelines provided by the Committee on Laboratory Animal Resources
and the NIH Office of Laboratory Animal Welfare (OLAW).
Apparatus
Each monkey lived in a well ventilated, stainless steel chamber for drug discrimination (56 ×
71 × 69 cm) or drug self-administration (60 × 100 × 76 cm) studies. An operant panel (28 ×
28 cm) was mounted on the front wall. Each panel contained three square translucent
response keys, arranged in a horizontal row, which could be transilluminated by red or green
stimulus lights, and a set of three vertical stimulus lights (red, green, yellow) located beneath
the center response key. A dispenser delivered 1-g banana-flavored food pellets to a
receptacle below the operant panel. Reinforcement schedules were controlled by IBM-
compatible computers and Med-Associates interface systems (St. Albans, VT) located in an
adjacent room.
Drug Discrimination
Discrimination studies were conducted to determine if modafinil shared stimulus
characteristics with cocaine and to assess the time course of discriminative stimulus effects.
As in our previous studies (Mello, Negus, Knudson, Kelly, & Mendelson, 2008; Negus,
Mello, Blough, Baumann, & Rothman, 2007), daily sessions consisted of 1 to 5 20-min
cycles. A 15-min time-out period was followed by a 5-min response period. During the
time-out, all stimulus lights remained off, and responding had no scheduled consequences.
During the response period, the right and left response keys were transilluminated red or
green, and monkeys could earn up to 10 food pellets by responding on a fixed-ratio 30
(FR30) schedule. For four monkeys, the left key was illuminated green, and the right key
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was illuminated red. The colors of the response keys were reversed for the other three
monkeys. If all available food pellets were delivered before the end of the 5-min response
period, the response key stimulus lights were turned off, and responding had no scheduled
consequences for the remainder of the 5-min period.
Training Procedure—Monkeys were trained to discriminate either a low or a high dose
of cocaine from saline. Three females were trained on a low dose of 0.18 mg/kg cocaine and
four males were trained on a high dose of 0.4 mg/kg cocaine. On training days, monkeys
were given an IM injection of cocaine or a similar volume of saline 5-min after the
beginning of each time-out period. Following saline administration, responding on only the
green, saline-appropriate key produced food, whereas following cocaine administration,
only responding on the red, drug-appropriate key produced food. Responses on the
inappropriate key reset the FR requirement on the appropriate key. Training days consisted
of 0 to 5 saline cycles followed by 0 to 1 drug cycles. Cocaine was administered only during
the last cycle.
Acquisition of cocaine discrimination was defined by meeting three criteria for 7 of 8
consecutive training sessions: 1) the percent injection-appropriate responding prior to
delivery of the first reinforcer was greater than or equal to 80% for all cycles; 2) the percent
injection-appropriate responding for each cycle was greater than or equal to 90%; and 3)
response rates during saline training cycles were greater than 0.5 responses per second.
Testing Procedure—Test sessions were identical to training sessions except that 1)
responding on either key produced food, and 2) a single injection of a test drug [saline,
cocaine (0.18 or 0.4 mg/kg)], amphetamine (0.032-0.32 mg/kg) or modafinil (3.2-32 mg/kg)
was administered IM at the beginning of the session, and 5-min response periods began after
10, 30, and 100 min. Additional response periods occurred at 60 min, 300 min and 24 h in
some cases.
Data Analysis—The mean ± SEM percent cocaine-appropriate responding (for the entire
response period) was plotted as a function of time after injection. Test drugs were
considered to substitute for the training dose of cocaine if they produced ≥90% cocaine-
appropriate responding. In addition, discrimination ED50 values were defined as the dose of
modafinil that produced 50% cocaine-appropriate responding. ED50 values were calculated
by linear interpolation in all monkeys in which modafinil dose-dependently produced >50%
cocaine-appropriate responding. ED50 values were calculated using data collected at 100
min, because this was the time of peak modafinil effect for both groups of subjects. Data
from individual subjects are also plotted. Response rate data for both groups are presented in
tabular format.
Cocaine self-administration
To permit intravenous drug delivery, a double-lumen catheter was surgically implanted into
each monkey under aseptic conditions as described previously (Mello et al., 2008). The
intravenous catheter was protected by a tether system consisting of a custom-fitted nylon
vest connected to a flexible stainless steel cable and fluid swivel (Lomir Biomedical Inc.,
Malone, NY). Two syringe pumps were mounted above each cage for delivery of saline or
drug solutions through the two lumens of the intravenous catheters. One syringe pump
delivered self-administered cocaine injections through one catheter lumen, and the second
syringe pump was used for non-contingent delivery of saline or modafinil through the
second catheter lumen.
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Procedures for evaluating the effects of modafinil on cocaine and food-maintained
responding were similar to those used in our previous studies (Mello, Lukas, Kamien,
Mendelson, & Cone, 1992; Mello & Negus, 1998; Negus & Mello, 2003; Negus et al.,
2007). Each session contained four experimental components and sessions were conducted 7
d/week. Food was available for self-administration at 11am, 3pm, 7pm, and 6am the next
morning, and the cocaine self-administration sessions began at 12pm, 4pm, 8pm, and 7am
the next morning. Room lights were off during all experimental sessions.
Training Procedure—The monkeys were trained to respond under an FR2 [VR16:S]
second-order schedule of reinforcement. At the beginning of each session, stimulus lights in
the center response key were illuminated (red for food, green for drug). Completion of a
variable ratio (VR) averaging 16 responses on the center key turned off the appropriate
colored stimulus light (red for food, green for cocaine) and turned on the appropriate colored
stimulus light located below the center response key for 1 s (VR16:S). Completion of two
VR16s (FR2) turned off the stimulus light illuminating the center response key and turned
on the appropriate colored stimulus light beneath it for 1 s and initiated delivery of a 1-g
banana-flavored food pellet or a 0.1 ml injection given over 1 s. Reinforcer delivery was
followed by a 10-s time-out period during which stimulus lights remained off and
responding had no scheduled consequences. If 25 food pellets or 20 injections were
delivered before expiration of the 1-hr session, then all stimulus lights were turned off, and
responding had no scheduled consequences for the remainder of that session. Thus, a
monkey could earn a maximum of 100 pellets/day and 80 injections/day. Only the center
key was active.
During training, responding was maintained by 1-g food pellets and 0.01 mg/kg/inj cocaine,
the lowest dose of cocaine that reliably maintained peak responding in all monkeys.
Training continued until monkeys met the following criteria for stable food and cocaine self-
administration under the FR2 [VR16:S] schedule of reinforcement: 1) three consecutive
days during which the number of drug injections/day varied by no more than 20% of the
three-day mean with no upward or downward trend in injection numbers, and 2) during the
same 3 consecutive days, the mean number of both food pellets and injections delivered per
day was greater than 60.
Chronic modafinil treatment—After responding stabilized according to the above
criteria, cocaine dose-effect relationships were determined during saline treatment. Monkeys
self-administered each unit dose of cocaine (0.001-0.1 mg/kg/inj) for at least 5 days and
until stability criteria were met or 10 days had elapsed, whichever occurred first. Cocaine
doses or saline were presented in an irregular order that differed for each monkey.
After determination of cocaine dose-effect curves during saline treatment, cocaine dose-
effect curves were redetermined during chronic modafinil treatment. Monkeys typically
remained at each cocaine dose for at least 7 days and until stability criteria were met or 10
days had elapsed, whichever occurred first. Modafinil was infused at a rate of 0.33 ml every
20 min from 10:30 am until 9:30 am the next day. Between 9:30 am and 10:30 am, monkeys
were fed, their health monitored, and modafinil catheter lines were flushed. The effects of 32
mg/kg/day modafinil were evaluated in four monkeys and the effects of 56 mg/kg/day
modafinil were evaluated in two monkeys. Tests with 56 mg/kg/day modafinil were not
completed in the other two monkeys because of stereotypies and difficulties maintaining
catheter patency during modafinil treatment. The doses of modafinil used for chronic studies
were empirically determined in pilot studies. Initial tests were conducted with 10 mg/kg
modafinil infused over one hour prior to the experimental session for 10 days. Neither
cocaine- nor food-maintained behaviors were altered by this dose of modafinil under those
conditions.
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Reinstatement by modafinil (32 and 56 mg/kg/day) during extinction—After
evaluation of chronic modafinil treatment on cocaine's self-administration was completed,
cocaine (0.01 mg/kg/inj) was made available for at least 10 days until responding stabilized
according to criteria stated above. Subsequently, saline was substituted for cocaine until
responding extinguished. Once the number of self-administered saline injections was <10
per day for three consecutive days, treatment with modafinil (32 and 56 mg/kg/day) was
begun in 3 monkeys and continued for 3 days. Prior to completing the reinstatement
experiments, the fourth monkey (monkey 13541), died due to causes unrelated to the study.
Data Analysis—The primary dependent variables were the total injections per day and
total pellets per day delivered during the last 3 days of each test period. ED50 values for
cocaine self-administration were defined as the dose of cocaine that produced 50% of
maximum possible numbers of injections per day (80 inj/day). For statistical analysis, the
effects of modafinil on food- and cocaine-maintained responding were analyzed by two-
factor analysis of variance (ANOVA) with treatment condition (saline vs modafinil) as one
factor and cocaine dose as the other factor. A significant ANOVA was followed by a
Bonferroni post hoc test when appropriate (P < 0.05). Repeated measures ANOVAs
followed by Dunnetts post hoc tests were used to analyze the effects of modafinil on
reinstatement responding (GraphPad Prism 4.0c for Macintosh; GraphPad Software Inc.).
Drugs—Cocaine hydrochloride (National Institute on Drug Abuse, Bethesda, MD) was
dissolved in sterile saline. Amphetamine sulfate (Sigma-Aldrich, St. Louis, MO) was
dissolved in sterile water. Modafinil was synthesized as described previously (Prisinzano,
Podobinski, Tidgewell, Luo, & Swenson, 2004). Initially, a vehicle of 1:1 ethanol:emulphor
was used for the animals trained to discriminate 0.18 mg/kg cocaine from saline in the
discrimination study. A vehicle of 40% beta-cyclodextrin was used for the group trained to
discriminate 0.4 mg/kg cocaine and for intravenous infusion in the self-administration study
(following dilution with sterile water). All drugs were sterile-filtered using a 0.22-μm
syringe filter (Millipore, Billerica, MA).
RESULTS
Discriminative stimulus effects of cocaine, amphetamine, and modafinil in monkeys
trained to discriminate 0.18 mg/kg cocaine from saline (Figures 1 and 2; Tables 1 and 3)
Control performance during training days—During the training days preceding test
days, the monkeys responded almost exclusively on the saline key during saline cycles
(mean % saline-appropriate responding = 99.91 ± 0.08) and almost exclusively on the
cocaine key during cocaine training sessions (mean % cocaine-appropriate responding =
99.74 ± 0.22). Mean response rates (±SEM) were 1.65 (±0.30) and 1.91 (±0.08) responses/s
during saline and drug training cycles, respectively.
Mean effects of cocaine, amphetamine and modafinil—Figure 1 shows group data
and Figure 2 shows individual data for the time course of the cocaine-like discriminative
stimulus effects of saline, cocaine, amphetamine, and modafinil in the group trained to
discriminate 0.18 mg/kg cocaine from saline (Upper panels). Saline administration produced
only saline-appropriate responding for the entire test period, whereas the training dose of
0.18 mg/kg cocaine produced peak levels of cocaine-appropriate responding after 10 min,
the same time interval used for training (training data not shown). The discriminative
stimulus effects of the cocaine-training dose decreased within 30 min and were no longer
apparent after 100 min. Amphetamine (0.032-0.1 mg/kg) produced a dose- and time-
dependent substitution for cocaine. Treatment with 0.032 mg/kg amphetamine produced a
maximum of 33% cocaine-appropriate responding for the group of three monkeys. The
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higher dose of 0.1 mg/kg amphetamine produced full substitution for cocaine in all three
monkeys 10-300 min after administration. The cocaine-like discriminative stimulus effects
of 0.1 mg/kg amphetamine were no longer apparent after 24hr. Pretreatment with 10 mg/kg
modafinil produced 100% cocaine-appropriate responding in 2 of 3 monkeys. Increasing the
dose of modafinil to 18 mg/kg produced 100% cocaine-appropriate responding in all three
monkeys. However, in contrast to cocaine and amphetamine, peak levels of substitution for
the group were not observed until 100 min after modafinil administration. The cocaine-like
discriminative stimulus effects of modafinil were still present at 300 min but were no longer
apparent after 24hr. The mean (95%CL) ED50 value of modafinil determined at the time of
peak effect (100 min) was 7.4 (4.2-13.3) mg/kg. Table 3 shows response rates for the time
course tests with saline, cocaine, amphetamine, and modafinil. Generally, rates of
responding were not affected by amphetamine, cocaine, or modafinil.
Discriminative stimulus effects of cocaine, amphetamine, and modafinil in monkeys
trained to discriminate 0.4 mg/kg cocaine from saline (Figures 1 and 2; Tables 2 and 4)
Control performance during training days—During the training days preceding test
days, the monkeys responded almost exclusively on the saline key during saline cycles
(mean % saline-appropriate responding = 99.92±0.07) and almost exclusively on the cocaine
key during cocaine training sessions (mean % cocaine-appropriate responding =
99.95±0.04). Mean response rates (±SEM) were 2.19 (±0.22) and 2.46 (±0.29) responses/s
during saline and drug training cycles, respectively.
Mean effects of cocaine, amphetamine and modafinil—Figure 1 shows group data
and Figure 2 shows individual data for the time course of the cocaine-like discriminative
stimulus effects of saline, cocaine, amphetamine and modafinil in monkeys trained to
discriminate 0.4 mg/kg cocaine from saline (Lower panels). Saline administration produced
only saline-appropriate responding for the entire test period, whereas the training dose of 0.4
mg/kg cocaine produced peak levels of cocaine-appropriate responding within 10 min, the
same time interval used for training (training data not shown). The discriminative stimulus
effects of the cocaine training dose then dissipated and were no longer apparent after 300
min. Amphetamine (0.1-0.32 mg/kg) produced a dose- and time-dependent substitution for
cocaine. The higher dose of amphetamine produced full substitution for cocaine in all four
monkeys with peak effects observed from 10 to 300 min after administration. Modafinil also
produced a dose- and time-dependent substitution for cocaine. Treatment with 18 mg/kg
modafinil produced full substitution for cocaine's discriminative stimulus effects in two of
four monkeys, and partial substitution in a third monkey. Increasing the dose to 32 mg/kg
produced complete substitution in this third monkey and partial substitution (67% cocaine-
appropriate responding) in the fourth monkey. Higher doses were not tested in this monkey
due to poor solubility of modafinil at higher concentrations. It is worth noting that the lower
dose of modafinil (10 mg/kg) substituted in the two monkeys for which the lower dose of
amphetamine, 0.1 mg/kg, also substituted for cocaine's discriminative stimulus. Conversely,
higher doses of both modafinil and amphetamine were necessary to produce cocaine-
appropriate responding in the other two monkeys. Peak levels of substitution for the group
were observed 30-100 min after modafinil administration. In this group, the discriminative
stimulus effects of the three drugs were evaluated at an additional time point (60 min), at
which the peak effects generally occurred. The cocaine-like discriminative stimulus effects
of modafinil then dissipated after 300 min. The mean (95% CL) ED50 value for the group
determined at 100 min was 18.7 (8.4-41.8) mg/kg. Generally, none of the drugs tested
altered response rates. However, in one monkey (RQB9), pretreatment with 18 mg/kg
modafinil produced a decrease in response rates 100 and 300 min following its
administration. Table 4 shows response rates for the time course tests with saline, cocaine,
amphetamine, and modafinil.
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Effects of modafinil on cocaine and food self-administration (Figures 3, 4, and 5)
Figure 3 shows data from the last three days of cocaine and food self-administration as a
function of cocaine dose during saline treatment conditions, and during chronic treatment
with modafinil in four monkeys. Cocaine self-administration during saline treatment was
dose-dependent, and the cocaine dose-effect curve generally had an inverted-U shape. A
one-way repeated measures ANOVA revealed a statistically significant effect of cocaine
dose [F (5, 15) = 51.62, P < 0.001]. Monkeys responded at low levels for saline injections
(points above ‘S’), and for the lowest dose of cocaine (0.001 mg/kg/inj). Cocaine (0.0032 –
0.1 mg/kg/inj) maintained significantly more responding than saline (P < 0.0001). Monkeys
responded at high, stable levels for food across all cocaine doses.
During chronic treatment with 32 mg/kg/day modafinil, the ascending limb and peak of the
cocaine dose-effect curve was shifted downward relative to the saline treatment condition. A
two-way repeated measures ANOVA revealed a significant effect of cocaine dose [F (5, 30)
= 68.56, P < 0.001], a significant treatment effect [F (1, 6) = 9.56, P < 0.05], and a
significant interaction between cocaine dose and treatment [F (5, 30) = 7.03, P < 0.001].
Post hoc tests revealed a significant difference between treatment with saline and 32 mg/kg/
day modafinil when 0.0032 mg/kg/inj cocaine was the available for self-administration (P <
0.001). Behavior maintained by the peak reinforcing dose of cocaine, 0.01 mg/kg/inj, was
also significantly reduced during modafinil treatment (P < 0.05). Responding maintained by
higher doses of cocaine (0.032 and 0.1 mg/kg/inj) was equivalent during the saline treatment
baseline and modafinil treatment conditions. Chronic treatment with 32 mg/kg/day
modafinil produced a 2.7-fold rightward shift in ED50 values calculated for the cocaine
dose-effect curve. The ED50 (95% CL) values for cocaine during saline treatment and
chronic modafinil treatment were 0.0020 mg/kg (0.0016-0.0024 mg/kg) and 0.0054 mg/kg
(0.0025-0.0115), respectively. Food-maintained behavior during saline treatment conditions
was stable across all doses of cocaine. No statistically significant difference in food-
maintained behavior was observed during chronic modafinil treatment.
Group data shown in Figure 3 are representative of the individual data shown in Figure 4.
Self-administration of 0.01 mg/kg/inj cocaine was reduced and the peak of the cocaine dose-
effect curve was shifted rightward during chronic treatment with modafinil in three of the
four monkeys. One exception to the group, monkey 21730, only showed decreased
responding at 0.0032 mg/kg/inj cocaine. Chronic modafinil treatment did not markedly alter
self-administration of 0.001 mg/kg/inj cocaine in any monkey. Self-administration of 0.0032
mg/kg/inj cocaine decreased in all monkeys during chronic treatment with modafinil. At
higher cocaine doses (0.032 and 0.1 mg/kg/inj) cocaine self-administration was comparable
to baseline conditions. All monkeys remained healthy and weights were stable during
chronic modafinil treatment. As noted earlier, one monkey (13541) died due to causes
unrelated to the study and was unable to complete his test with the saline + 32 mg/kg/day
modafinil condition.
Two monkeys (monkeys 21730 and C0X) were tested at a higher dose of 56 mg/kg/day
modafinil (data not shown). In monkey 21730, this dose of modafinil produced similar
effects as treatment with 32 mg/kg/day, in that it reduced self-administration of 0.0032 mg/
kg/inj, but not 0.01 mg/kg/inj cocaine. In monkey C0X, 56 mg/kg/day modafinil decreased
cocaine self-administration (0.0032 mg/kg/inj) more than treatment with 32 mg/kg/day, but
self-administration of 0.01 and 0.032 mg/kg/inj was not affected. Daily treatment with 56
mg/kg/day produced a reduction of food-maintained responding for the first seven days of
treatment in both monkeys, and reduced food intake in monkey C0X. Both monkeys
developed stereotypies characterized by focused grooming and prolonged downward gazing.
Chronic testing with 56 mg/kg/day modafinil was not completed in the other two monkeys
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because of stereotypies and difficulties maintaining catheter patency during the 7-10 day
modafinil treatment period.
Reinstatement of cocaine-seeking behavior by acute modafinil—After a drug-
free period, three of the same monkeys were used to test the effects of modafinil on
extinguished responding. Saline was substituted for the maintenance dose of cocaine, 0.01
mg/kg/inj, until responding extinguished (< 10 injections for three consecutive days), which
occurred after a mean of 10.7 days. After extinction, modafinil treatment (32 or 56 mg/kg/
day) was introduced and responding maintained by saline was observed for three days.
Figure 5 shows numbers of saline injections for the group (bars) as well as individuals
(symbols) for the mean of the last three days of extinction and on each of the three
consecutive days of treatment with 32 mg/kg/day modafinil (Upper figure) and 56 mg/kg/
day modafinil (Lower figure). During the first day of modafinil treatment (32 mg/kg/day),
responding for saline increased significantly from the previous day's extinction levels [F (3,
11) = 7.97, P < 0.05]. Dunnett's post hoc tests revealed a significant increase on the first day
of modafinil treatment (P < .01), but not days 2 and 3. Infusion of 56 mg/kg/day modafinil
also produced a significant increase in saline self-administration [F (3, 11) = 4.70, P = 0.05],
and again, the numbers of self-administered saline injections were significantly greater on
the first treatment day only (P < 0.05).
DISCUSSION
The present studies were designed to evaluate modafinil as a candidate medication for
treating cocaine abuse disorders. This is the first preclinical study to demonstrate that
chronic modafinil treatment selectively reduced cocaine self-administration by rhesus
monkeys. The rhesus monkey drug self-administration model is valuable for evaluation of
potential drug abuse treatment medications, and shows high concordance with clinical
treatment trials (Haney & Spealman, 2008; Mello, 2005; Mello & Negus, 1996). The major
findings of the present study are consistent with clinical laboratory studies and outpatient
trials of modafinil effects on the abuse-related effects of cocaine described below. Cross-
validation of preclinical and clinical evaluations of drug abuse treatment medications is very
important because novel medications that appear to reduce cocaine self-administration in
preclinical models often are not FDA-approved for human testing (Mello, 2005).
Agonist-based pharmacotherapies are often more effective than antagonist-based
pharmacotherapies and are more acceptable to patients (Grabowski et al., 2004; Mello &
Mendelson, 1995; Mendelson & Mello, 1996). One important feature of agonist-based
pharmacotherapies is that they retain behavioral and pharmacological features of the abused
drug (Grabowski et al., 2004). To more fully characterize the behavioral interactions
between modafinil and cocaine, the similarities between these drugs were assessed in a drug
discrimination procedure and in a reinstatement procedure. We found that modafinil
produced a dose- and time-dependent substitution for the discriminative stimulus effects of
cocaine, and this is consistent with clinical reports (Rush, Kelly, Hays, & Wooten, 2002).
Modafinil significantly reinstated responding previously reinforced by cocaine, further
suggesting its similarity to cocaine. Finally, chronic administration of modafinil on cocaine-
and food-maintained behavior was evaluated. We found that modafinil selectively attenuated
the reinforcing effects of cocaine doses on the ascending limb of the cocaine dose-effect
curve. Some implications of these findings and limitations of the study are discussed below.
Cocaine-like Discriminative Stimulus Effects of Modafinil
We compared the effects of modafinil in rhesus monkeys trained to discriminate low and
high cocaine doses, in part because it has been suggested that use of a lower training dose
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may reduce the pharmacological selectivity of the training cue and increase the maximal
effects of individual drugs and/or the overall range of drugs that produce substitution
(Stolerman, 1993; Terry, Witkin, & Katz, 1994). Modafinil produced cocaine-like
discriminative stimulus effects in monkeys trained to discriminate both low and high doses
of cocaine from saline. These data in rhesus monkeys are generally consistent with previous
reports in rats showing that modafinil partially substitutes for cocaine in a dose- (Gold &
Balster, 1996) and time- dependent manner (Dopheide et al., 2007). Modafinil doses up to
100 mg/kg did not substitute for cocaine; however, a dose of 250 mg/kg produced full
substitution, but markedly reduced responding in four of six rats (Gold & Balster, 1996).
Orally administered modafinil also substituted for cocaine in two groups of rats trained to
discriminate different doses of cocaine, in a dose- and time-dependent manner (Dopheide et
al., 2007). Peak effects of oral modafinil occurred between 60-120 min, similar to onset of
peak effects following IM administration in monkeys in the present study. These data
indicate that modafinil's onset of action is slower than that of both cocaine and
amphetamine, and its duration of action for producing cocaine-like discriminative stimulus
effects is shorter than that of amphetamine. Taken together, these data indicate that
modafinil engenders partial to full substitution for cocaine at doses 25-80 times greater than
the training dose of cocaine. Similarly, a dose of modafinil 4 times greater than the training
dose (600 mg modafinil) fully substituted for cocaine in three of six human subjects trained
to discriminate effects of oral cocaine from placebo (Rush, Kelly, Hays, & Wooten, 2002).
Limitations in modafinil solubility prevented administration of the higher doses in rat
studies, and doses in human studies were presumably limited by ethical and safety
considerations. However, authors of all these studies speculated that higher modafinil doses
might have produced higher levels of cocaine-appropriate responding. The results of the
present study support this conclusion and demonstrate good concordance between species
for the cocaine-like discriminative stimulus effects of modafinil.
Interestingly, the ED50 value for modafinil in the lower dose training group (7.4 mg/kg) was
similar to the modafinil dose that occupied 54% of striatal dopamine transporters in PET
studies conducted in rhesus monkeys (8 mg/kg IV, Madras et al., 2006). The doses that
produced cocaine-like discriminative stimulus effects in the present study are also similar to
(a) doses used clinically to promote wakefulness in humans (100-600 mg, or roughly 1.5-10
mg/kg), and (b) doses that maintain self-administration and decrease cocaine consumption in
human laboratory and outpatient studies (200-400 mg, or roughly 3-8 mg/kg) (Dackis et al.,
2005; Hart et al., 2008; Stoops et al., 2005). In comparison to cocaine and amphetamine,
modafinil had at least 100-fold lower potency and a slower onset of action. The low potency
and slow onset of modafinil likely contribute to modafinil's relatively low abuse liability
(Myrick et al., 2004)
The extent to which sex differences may have contributed to the apparent differences
between the low and high dose training groups cannot be determined with certainty from
these data. The low dose (0.18 mg/kg) cocaine training group consisted of only females,
whereas the high dose (0.4 mg/kg) cocaine training group consisted only of males. Whether
or not there are sex differences in cocaine's discriminative stimulus effects has not been
evaluated in rhesus monkeys. However, studies using rodents (Anderson & van Haaren,
1999; Craft & Stratmann, 1996) reported no sex differences, and studies using humans
reported no effect of sex or menstrual cycle phase on subjective effects produced by cocaine
in humans (Collins, Evans, Foltin, & Haney, 2007; Mendelson et al., 1999; Singha,
McCance-Katz, Petrakis, Kosten, & Oliveto, 2000). One exception to this general finding is
that smoked cocaine appears to produce weaker subjective effects during luteal phase than
during the follicular phase or in men (Evans, Haney, & Foltin, 2002; Sofuoglu, Dudish-
Poulsen, Nelson, Pentel, & Hatsukami, 1999). Also, no effects of sex or menstrual cycle
phase have been reported in clinical studies that examined the discriminative stimulus of
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modafinil (Rush, Kelly, Hays, & Wooten, 2002). However, one report suggested that
females may be more sensitive to the stimulant effects of high doses (800 mg) of modafinil
(referenced in Jasinski & Kovacevic-Ristanovic, 2000).
A second difference was that the two training groups were administered modafinil in
different vehicles. In the 0.18 mg/kg training group, modafinil was administered in a 1:1
ethanol: emulphor vehicle, and in the 0.4 mg/kg training group, modafinil was administered
in a 40% beta cyclodextrin vehicle. The vehicles could influence the rate of absorption, and
potentially alter the onset of stimulus effects. However, the time course of modafinil's
effects were comparable between the two training groups, suggesting that differences in
potency for producing cocaine-like discriminative stimulus effects were not attributable to
the use of different vehicles.
Effects of Chronic Modafinil Administration on Food- and Cocaine-Maintained Responding
Chronic IV treatment with 32 mg/kg/day modafinil produced a rightward shift in the
ascending limb and peak of the cocaine self-administration dose-effect curve (0.0032 and
0.01 mg/kg/inj). Modafinil had no effect on self-administration of higher doses of cocaine,
suggesting that effects of modafinil are surmountable. This is consistent with the common
finding that behavior maintained by lower unit doses is more vulnerable to modification by
pharmacological treatments (for a discussion see Mello & Negus, 1996). Importantly,
chronic treatment with 32 mg/kg/day modafinil did not change food-maintained responding,
indicating that the reduction of cocaine self-administration was not due to general
suppression of responding. Chronic treatment with this dose also did not produce any overt
behavioral effects, and did not reduce consumption of food given outside of experimental
sessions.
This is the first evaluation of chronic modafinil treatment on cocaine self-administration in
cocaine-experienced rhesus monkeys. The present results are consistent with the findings of
a clinical laboratory study of the effects of modafinil maintenance on cocaine's reinforcing
effects (Hart et al., 2008). In that study, cocaine-dependent subjects were maintained on
placebo, 200 mg, or 400 mg modafinil over a 48-day period and given the opportunity to
choose between cocaine and money. Both doses of modafinil significantly reduced the
number of cocaine choices across a range of cocaine doses. Our findings are not consistent
with the one previous study in rats in which modafinil failed to alter cocaine self-
administration (Deroche-Gamonet et al., 2002). That study examined acute doses of 32-128
mg/kg modafinil administered 20 min before each 60 or 130 min session. Modafinil has a
slow onset of action and peak effects usually occur within 60-100 min. Thus, modafinil may
not have been maximally effective at time of testing in rats.
The effects of modafinil observed in the present study are consistent with results of previous
studies showing that DAT inhibitors selectively reduce cocaine self-administration in
monkeys. In particular, GBR12909, a high affinity DAT inhibitor, reduced rates of
responding maintained by cocaine at doses that did not alter rates of responding maintained
by food (Glowa et al., 1995). The effects of GBR12909 were also dependent upon the dose
of cocaine available for self-administration. Specifically, GBR12909 produced a downward
shift in the ascending limb and peak of the cocaine self-administration dose-effect curve, but
rates maintained by higher cocaine doses were not affected. GBR12909 was under
consideration as a candidate agonist-based pharmacotherapy, but reports of potential adverse
cardiovascular effects during a phase I clinical trial halted further investigation (Vocci, Acri,
& Elkashef, 2005). Modafinil has been extensively evaluated for safety, and appears to have
no adverse toxicological consequences by itself or when combined with cocaine (Dackis et
al., 2003; Donovan et al., 2005; Hart et al., 2008; Malcolm et al., 2006).
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Previous work in our laboratory demonstrated that chronic treatment with selective
monoamine releasers, d-amphetamine (Negus & Mello, 2003; Negus et al., 2007), and
phenmetrazine (Negus, Baumann, Rothman, Mello, & Blough, 2009), produced selective
reductions in cocaine-maintained responding. However, DAT inhibitors, indatraline,
RTI-112 and RTI-113, were non-selective and reduced both cocaine and food-maintained
responding (Negus, Brandt, & Mello, 1999; Negus, Mello, Kimmel, Howell, & Carroll,
2009), suggesting that high affinity and pharmacological selectivity for DAT is not
sufficient to selectively reduce cocaine-maintained responding. Although medication-
induced increases of extracellular dopamine appears to be a critical feature of agonist-based
pharmacotherapies, the mechanism and influence of other monoamine transmitters remains
to be determined.
Study Strengths and Limitations
One strength of the present study is that modafinil was administered every 20 min for 23 hr
each day to ensure that stable levels were present during cocaine dose-effect curve
determinations. One limitation of the present study is that plasma levels of modafinil were
not measured. In clinical treatment trials, 200-400 mg modafinil is administered orally once
or twice daily. The dose of modafinil that effectively reduced cocaine self-administration in
the present study was greater than clinically relevant doses. Comparing plasma levels of
modafinil obtained in the monkey to known effective values in humans would be useful in
determining whether the dose of modafinil used in the present study produced levels
comparable to those obtained clinically.
Implications for modafinil as a candidate agonist medication
Abuse Liability—The finding that modafinil both substituted for the discriminative
stimulus effects of cocaine and renewed extinguished responding of saline self-
administration could be interpreted to suggest that modafinil has a cocaine-like abuse
liability. In agreement with this view, modafinil also maintained self-administration in
rhesus monkeys (Gold & Balster, 1996) and under some (Stoops et al., 2005), but not all
(Vosburg et al., 2010) conditions in humans. Three factors appear to mitigate the abuse
liability of modafinil in comparison to other CNS stimulants. First, as described above,
modafinil has extremely low potency, and as a result, very high doses are required to
produce prominent stimulant effects. Even under the best circumstances, it would be
logistically difficult to obtain and consume such high doses. For example, data from both
monkeys and rats suggest that modafinil is approximately 100-fold less potent than cocaine
in drug discrimination procedures. A second factor that may limit the abuse liability of
modafinil is its relatively slow onset compared to stimulants such as cocaine or
amphetamine. In the present study, peak effects of cocaine and amphetamine were generally
observed at 10 min, whereas peak effects of modafinil were not observed until 60-100
minutes after administration. Rate of onset appears to be one factor that influences the
reinforcing effects of drugs, and slower onsets have been associated with lower reinforcing
effects (Balster & Schuster, 1973; Winger, Hursh, Casey, & Woods, 2002). Finally, the low
solubility and heat sensitivity of modafinil function as physical barriers to the use of
modafinil by parenteral routes. Modafinil is insoluble in water at significant concentrations,
and potentially noxious vehicles are necessary to produce solutions that can be delivered
parenterally (Dopheide et al., 2007; Gold & Balster, 1996). Moreover, even with optimal
vehicles, solubility is limited to relatively low concentrations that require high injection
volumes.
Concordance Between Clinical and Non-human Primate Studies—Clinical
studies evaluating modafinil as a candidate agonist-based pharmacotherapy have provided
some encouraging results. Findings from clinical laboratory studies showed that modafinil
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attenuated the positive subject-rated effects of IV cocaine (Dackis et al., 2003; Malcolm et
al., 2006). As noted earlier, another clinical laboratory study found that modafinil (200 and
400 mg) reduced smoked cocaine self-administration and positive subjective-effect ratings
(Hart et al., 2008). Results of an 8-week open-label, outpatient clinical trial demonstrated
that subjects receiving modafinil achieved three weeks or more of abstinence and provided
significantly fewer positive urine samples, however, the treatment group had fewer cocaine
positive urine samples at baseline (Dackis et al., 2005). Most recently, a multi-site outpatient
clinical trial demonstrated that, over a 12-week period, modafinil produced a nonsignificant
trend in reduced cocaine use relative to placebo treatment (Anderson et al., 2009).
Importantly, when a subgroup of subjects with co-morbid alcohol dependence was removed
from the analyses, a reduction of cocaine use in subjects receiving modafinil achieved
statistical significance. Overall, the positive results of clinical studies are consistent with the
effects of modafinil observed in the current study.
The major findings of the present study reaffirm the usefulness of preclinical drug self-
administration procedures as models of human drug abuse. A recent review by Haney and
Spealman (2008) outlined the corresponding outcomes between preclinical self-
administration studies and clinical measures. The present findings support the conclusion
that preclinical drug self-administration models can predict the effectiveness of
pharmacotherapies for drug abuse treatment. For example, studies evaluating buprenorphine
(Mello, Kamien et al., 1993; Mello, Mendelson et al., 1993), d-amphetamine (Negus &
Mello, 2003; Negus et al., 2007), and now modafinil, provide considerable evidence of the
concordance between the results of clinical treatment trials and preclinical findings (Mello,
2005).
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Effects of saline, cocaine, amphetamine, and modafinil in three female rhesus monkeys
trained to discriminate 0.18 mg/kg cocaine from saline (Upper panels) and four male rhesus
monkeys trained to discriminate 0.4 mg/kg cocaine from saline (Lower panels). Each data
point represents mean ± SEM data from a single determination. Abscissae: min or hr after
drug or saline administration. Ordinates: Percent cocaine-appropriate responding.
Newman et al. Page 17














Discriminative stimulus effects of modafinil in three individual monkeys trained to
discriminate 0.18 mg/kg cocaine from saline (Upper panels) and in four individual monkeys
trained to discriminate 0.4 mg/kg cocaine from saline (Lower panels). Abscissae: min or hr
after drug administration. Ordinates: Percent cocaine-appropriate responding. All points
show data from a single determination in each monkey. The identification number for each
monkey is shown in the upper left of each panel.
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Effects of modafinil on the cocaine self-administration dose-effect curve and concurrent
food-maintained responding in four monkeys. Abscissae: Unit dose of cocaine (mg/kg/inj)
available during daily drug components. Points above ‘S’ show data collected when saline
was the solution available for self-administration. Ordinate (Upper panel): Mean ±SEM
numbers of cocaine injections self-administered per day during saline treatment baseline
conditions (open symbols) and during chronic modafinil treatment (filled symbols). Each
data point is the average of the last three days of each cocaine dose condition. Ordinate
(Lower panel): Mean ±SEM numbers of food pellets delivered per day during saline
treatment baseline conditions (open symbols) and during chronic modafinil treatment (filled
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symbols). All data points show data from four monkeys, except for saline + modafinil which
shows data from three monkeys. *P < 0.05 **P < 0.01, compared to baseline.
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Effects of modafinil on the cocaine self-administration dose-effect curve in individual
monkeys. Ordinate: numbers of cocaine injections self-administered per day during baseline
conditions (open symbols) and during chronic modafinil treatment (filled symbols). Points
above ‘S’ show data collected when saline was the solution available for self-administration.
Each data point shows the mean ±SEM from the last three days of each cocaine dose
condition. The identification number for each monkey is shown in the upper left of each
panel.
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Effects of modafinil on extinguished responding. Ordinates: Numbers of saline injections
self-administered during extinction and on three consecutive days of 32 mg/kg/day of
modafinil treatment (Upper panel) and 56 mg/kg/day of modafinil treatment (Lower panel).
Each bar represents the mean number of saline injections/day by a group of three monkeys,
and the closed symbols show each individual monkey's data. Abscissae: Treatment day. The
column above ‘Extinction’ show mean saline injections from the last three days of extinction
prior to the introduction of modafinil. Treatment days 1, 2, and 3 are saline injections from
the first, second, and third day of modafinil treatment, respectively.
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Table 1
Maximum percent Cocaine-Appropriate Responding (%CAR) Observed during Substitution Experiments with
Cocaine, Amphetamine and Modafinil in a Group of Monkeys Trained to Discriminate 0.18 mg/kg Cocaine
from Saline.
Drug Dose range tested (mg/kg; IM) Maximum %CAR # of monkeys substituting1 N2
Cocaine 0.18 100 3 3
Amphetamine 0.032-0.1 100 3 3
Modafinil3 3.2-18 100 3 3
1
Total number of monkeys in which the test drug produced ≥90% CAR.
2
Indicates total number of animals tested.
3
Data obtained 100 min following modafinil administration.
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Table 2
Maximum percent Cocaine-Appropriate Responding (%CAR) Observed during Substitution Experiments with
Cocaine, Amphetamine and Modafinil in a Group of Monkeys Trained to Discriminate 0.4 mg/kg Cocaine
from Saline.
Drug Dose range tested (mg/kg; IM) Maximum %CAR # of monkeys substituting1 N2
Cocaine 0.4 100 3 3
Amphetamine 0.032-0.1 100 3 3
Modafinil3 3.2-18 100 2 4
32 75 1 2
1
Total number of monkeys in which the test drug produced ≥90% CAR.
2
Indicates total number of animals tested.
3
Data obtained 60 min following modafinil administration
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